Thank you for Subscribing to Healthcare Business Review Weekly Brief
StimLabs is expanding its product line to meet the increasing variety of needs in healthcare facilities.
FREMONT, CA: Patients are monitored using a patient monitoring system, which enables medical professionals to keep track of patients' health away from the hospital. It allows them to check the changes in a patient's health data in real-time and utilize that information to plan the patient's care and safety. Enverse, a new placental membrane-based product, is unveiled by StimLabs, one of the pioneers in regenerative technologies and products that are redefining patient care via innovation and customized solutions.
In response to a widening range of needs in healthcare facilities, StimLabs is expanding its product portfolio. Aiming to simplify patient care for both physicians and the hospital systems in which they practice, StimLabs unveiled Enverse. In addition to physician-owned facilities, hospitals also have access to StimLabs' solutions.
Dehydrated complete human placental membrane (dCHPM) allograft Enverse is designed to cover acute and chronic wounds. In healthcare, leveraging the patented ClearifyTM method, the intermediate layer is retained in the dCHPM allograft. This allograft is stabilized into a compact, translucent form through a patented oven-dehydration process. In addition to providing excellent handling characteristics, Enverse increases application site visibility.
Each product in StimLabs' distinct placental membrane-based product portfolio is processed utilizing the company's patented Clearify process, ensuring the highest level of quality. With a focus on identifying, optimizing, and preserving native structures and structural elements present in natal tissue, StimLabs develops processes using a scientific method. StimLabs continues to reinvent the tissue space and provide market-leading products with the ultimate goal of preserving all the potential that birth tissue has to offer.